跳至主要内容

Custom Peptide Synthesis

MuseChem is a leading supplier of custom peptide synthesis services. With rich knowledge and expertise in peptide synthesis and proprietary platform technologies, we offer a wide range of peptide synthesis services from bulk API peptides production to complex peptide modifications. We have an experienced team of scientists who are able to choose and optimize the appropriate peptide synthesis method for each peptide, so our peptide synthesis service has a very high success rate. Each peptide comes with a complete quality control package, which includes HPLC and MS Analysis. Features of our custom peptide synthesis ● Free peptide design and consultation ● Custom synthesis of peptide, peptides building blocks and peptide fragments ● Small scale high throughput peptide library synthesis to bulk quantity peptides production ● Solid and solution phase synthesis ● Recombinant peptide technology for producing long peptide (>200 amino acids) ● State-of-the-art analytical support (LCMS, HPLC, AA analyzer) Custom synthesis of modified peptides MuseChem also has a strong capability in supplying a variety of modified peptides, include, not limited to: ● Isotope labeled peptides ● Fluorescent & FRET peptides ● Cyclic peptides ● Stapled peptides ● Amidated peptides ● Acetylated peptides ● Biotinylated peptides ● Citrullinated peptides ● Phosphorylated peptides ● PEGylated peptides

评论

此博客中的热门博文

E 3810 is in stock now!

First-in-class dual VEGFR/FGFR tyrosine kinase inhibitor; E-3810 potently and selectively inhibited VEGFR1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range; a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity

A major introduction to Autophinib!

Autophinib(cas 1644443-47-9) is a potent autophagy inhibitor, which can inhibit autophagy induced by starvation or rapamycin by targeting the lipid kinase VPS34 with IC50s of 90, 40 and 19 nM, respectively.

GW590735 CAS No. : 622402-22-6 is in stock now!

GW590735 is a potent and selective agonist of PPARα with an EC50 value of 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivity versus PPARγ and PPARδ. GW590735 significantly increased HDL cholesterol, decreased LDL and VLDL cholesterol, and significantly reduced triglycerides. Maximal increases in HDL cholesterol were 37%, 53%, and 84% with fenofibrate, torcetrapib, and GW590735, respectively.